COMPASS Pathways

Compass Pathways Plc functions as an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

COMPASS Pathways reports Q4 earnings, faces challenges, explores opportunities

COMPASS Pathways showcased progress in its clinical programs, financial performance, and strategic initiatives. Despite challenges in trial protocols and financial losses, the company remains focused on advancing its treatment options and exploring growth opportunities.

COMPASS Pathways advances Phase 3 TRD program amidst financial challenges

COMPASS Pathways is making progress in their Phase 3 TRD program and maintaining a strong financial position for future developments.
Acceptance of new CPT codes and engagement with health systems present growth opportunities for the company.
However, challenges like financial losses, mixed views on commercialization, and operational differences exist.
Overall, COMPASS Pathways is strategically positioned to capitalize on the evolving landscape of psychedelic therapies.

COMPASS Pathways progresses in trials amidst market challenges and opportunities

COMPASS Pathways is advancing well in trials for treatment-resistant depression and strengthening its market position through IP protection and regulatory milestones.
Challenges lie in differentiation from competitors and establishing unique value propositions, but opportunities exist in FDA support, market growth, and funding flexibility.
Overall, the company's performance, financial stability, and strategic moves position it favorably in the evolving landscape of psychedelic therapies.

COMPASS Pathways reports strong Q3 earnings, eyes transformative 2024

COMPASS Pathways demonstrated robust financial performance in Q3 2023, with strong cash reserves and a strategic private placement financing, positioning the company well for upcoming milestones.
While facing challenges in patient recruitment and trial complexities, COMPASS is leveraging AI models and expanding clinical sites to optimize operations and drive therapeutic innovation.
With Phase III data on the horizon and ongoing advancements in research and development, COMPASS Pathways is poised for a transformative year in 2024, capitalizing on growth opportunities and research insights.

COMPASS Pathways advances COMP360 trials amid financial challenges

COMPASS Pathways' financials show investment in research and development despite net losses, with a strong cash position.
Progress in key trials for COMP360 in TRD and positive safety data indicate promising developments in mental health treatment.
Challenges in enrollment, delays in data, and regulatory monitoring require strategic navigation for future success.
Opportunities lie in collaborations, potential indications, and a focused approach to TRD treatment with COMP360.

COMPASS Pathways advances in clinical trials and strategic partnerships

COMPASS Pathways showcased strong clinical and financial performance in Q1 2024 earnings call, emphasizing progress in Phase III trials and positive PTSD study results
While facing challenges in risk mitigation and therapy comparisons, the company's strategic collaborations and upcoming data releases offer promising opportunities for growth

Compass Pathways faces trial delays, strengthens leadership for commercial success

Compass Pathways navigates delays in pivotal trials while focusing on data disclosure and commercial readiness. New leadership strengthens strategic direction and commercial landscape. Challenges include trial complexities and managing attrition rates, with opportunities in leveraging Phase III data and commercial collaborations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Atai Life Sciences BV

It's risky, and you'll need to wait a while for a payoff, assuming the stars align for there to be one.

Is Now a Good Time to Invest In Psychedelics Stocks?

LONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at Jefferies Innovation in Mental Health Summit at 8:30am ET on 22 September 2022.

COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit

They haven't experienced any setbacks, but their shares are still down.

Buying These 2 Battered Growth Stocks Right Now Could Be Brilliant

This week, we're talking about my Big Three investing themes for the rest of the year (and beyond). You've probably heard me talk about each at one point or another.

Compass Pathways (CMPS): The McDonald's of Psychedelics?

These two trends on the frontier of medicine could present lucrative opportunities for investment.

2 Top Trends to Invest $2,000 in Ahead of the Crowd

LONDON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three upcoming investor events as follows:

COMPASS Pathways to participate in three upcoming investor events

Cybin

Ameri Holdings

GH Research PLC

Mind Medicine MindMed

Advisorshares Psychedelics ETF

Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and sensory perceptions.

7 Psychedelics Stocks to Buy for a Big Drug Boom

Wall Street is growing increasingly bullish about the drugmaker's prospects.

Why Compass Pathways Stock Blasted Higher This Week

RUTHERFORD, Calif.--(BUSINESS WIRE)--One Mind, in collaboration with COMPASS Pathways plc, has announced the recipients of three “2022 One Mind – COMPASS Rising Stars Awards."

One Mind Announces the Winners of the 2022 Rising Star Awards for Mental Health Research

OrthoPediatrics

Nano-X Imaging

Here's why OrthoPediatrics, Compass Pathways, and Nano-X Imaging look like great stocks.

3 Stocks to Buy and Hold for the Long Term

COMPASS Pathways is developing a psychedelic drug to treat many mental illnesses. The drug appears to be safe and effective for a wide range of mental health problems.

COMPASS Pathways And The Trillion Dollar Opportunity

The incredible healing properties of psychedelics are being discovered with every passing day. Their potential is massive and can flip the script for those struggling with mental health disorders.

3 Best Psychedelic Stocks to Buy Now

The consensus price target hints at a 288.6% upside potential for COMPASS Pathways PLC Sponsored ADR (CMPS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 289% Upside in COMPASS Pathways PLC Sponsored ADR (CMPS): Can the Stock Really Move This High?

COMPASS Pathways plc (NASDAQ:CMPS ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Steven Schultz - Senior Vice President, Investor Relations George Goldsmith - Co-Founder and CEO Dr. Guy Goodwin - Chief Medical Officer Mike Falvey - Chief Financial Officer Kabir Nath - New Chief Executive Officer Conference Call Participants Ritu Baral - Cowen Neena Bitritto-Garg - Citi Patrick Trucchio - H.C. Wainwright Charles Duncan - Cantor Fitzgerald Sumant Kulkarni - Canaccord Genuity Francois Brisebois - Oppenheimer Elemer Piros - ROTH Bert Hazlett - BTIG Michael Okunewitch - Maxim Group Operator Good day, ladies and gentlemen, and welcome to COMPASS Conference Call.

COMPASS Pathways plc's (CMPS) CEO George Goldsmith on Q2 2022 Results - Earnings Call Transcript

LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2022 and gave an update on recent progress across its business.

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

Defiance Next Gen Altered Experience ETF

PSYK ETF

Seelos Therapeutics

On July 13, 2022, two amendments passed in the House of Representatives that would provide psychedelic drug treatment to veterans and active duty service members. A documentary based on Michael Pollan's 2018 book, "How to Change Your Mind," is one of Netflix's most-watched shows.

The Growth Potential Of Psychedelics Stocks And ETFs

Multi-centre, d ouble-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therap y in anorexia nervosa for which there is currently no approved pharmacological treatment option

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa

LONDON, July 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2022, and provide an update on recent business developments on 4 August 2022.

COMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022

Psychedelic stocks are in focus following new legislation from both the Senate and the House that has bipartisan support. The post Dear Psychedelic Stocks Fans, Watch This Key Catalyst appeared first on InvestorPlace.

Dear Psychedelic Stocks Fans, Watch This Key Catalyst

Kabir Nath will build upon COMPASS' success and lead the development of novel models of care to accelerate patient access to evidence-based innovation in mental health care

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

The average of price targets set by Wall Street analysts indicates a potential upside of 781.4% in COMPASS Pathways PLC Sponsored ADR (CMPS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 781% Upside in COMPASS Pathways PLC Sponsored ADR (CMPS): Can the Stock Really Move This High?

Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression

COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting

LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming events as follows:

COMPASS Pathways to participate in upcoming Citi's Biopharma Virtual Co-Panel Day and H.C. Wainwright Global Investment Conference

COMPASS Pathways plc (NASDAQ:CMPS ) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Steven Schultz - SVP, IR George Goldsmith - Chairman & CEO Guy Goodwin - Chief Medical Officer Mike Falvey - CFO Conference Call Participants Josh Schimmer - Evercore ISI Charles Duncan - Cantor Fitzgerald Neena Bitritto-Garg - Citi Ritu Baral - Cowen Bert Hazlett - BTIG Francois Brisebois - Oppenheimer Elaine Kim - Berenberg Patrick Trucchio - HC Wainwright Operator Good morning, and welcome to COMPASS Pathway's First Quarter ‘22 Earnings Call. During the presentation, all participants will be in a listen-only mode.

COMPASS Pathways plc (CMPS) CEO George Goldsmith on Q1 2022 Results - Earnings Call Transcript

LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2022 and gave an update on recent progress across its business.

News for COMPASS Pathways Stock (CMPS)